Antivirals against enterovirus 71 (EV71) are urgently needed. We demonstrate that the novel enteroviral protease inhibitor (PI) SG85 and capsid binder (CB) vapendavir efficiently inhibit the in vitro replication of 21 EV71 strains/isolates that are representative of the different genogroups A, B, and C. The PI rupintrivir, the CB pirodavir, and the host-targeting compound enviroxime, which were included as reference compounds, also inhibited the replication of all isolates. Remarkably, the CB compound pleconaril was devoid of any anti-EV71 activity. An in silico docking study revealed that pleconaril-unlike vapendavir and pirodavir-lacks essential binding interactions with the viral capsid. Vapendavir and SG85 (or analogues) should be further explored for the treatment of EV71 infections. The data presented here may serve as a reference when developing yet-novel inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249361 | PMC |
| http://dx.doi.org/10.1128/AAC.03328-14 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Virus adaptation to heparan sulfate comes with capsid stability tradeoff.
Elife
December 2024
Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.
Because of high mutation rates, viruses constantly adapt to new environments. When propagated in cell lines, certain viruses acquire positively charged amino acids on their surface proteins, enabling them to utilize negatively charged heparan sulfate (HS) as an attachment receptor. In this study, we used enterovirus A71 (EV-A71) as the model and demonstrated that, unlike the parental MP4 variant, the cell-adapted strong HS-binder MP4-97R/167 G does not require acidification for uncoating and releases its genome in the neutral or weakly acidic environment of early endosomes.
View Article and Find Full Text PDFProtein-protein interactions (PPIs) are at the core of all key biological processes. However, the complexity of the structural features that determine PPIs makes their design challenging. We present BindCraft, an open-source and automated pipeline for protein binder design with experimental success rates of 10-100%.
View Article and Find Full Text PDFSAR Analysis of Novel Coxsackie virus A9 Capsid Binders.
J Med Chem
October 2024
Department of Drug Chemistry and Technologies, Sapienza University of Rome, 00185 Rome, Italy.
Enterovirus infections are common in humans, yet there are no approved antiviral treatments. In this study we concentrated on inhibition of one of the (EV-B), namely Coxsackievirus A9 (CVA9), using a combination of medicinal chemistry, virus inhibition assays, structure determination from cryogenic electron microscopy and molecular modeling, to determine the structure activity relationships for a promising class of novel -phenylbenzylamines. Of the new 29 compounds synthesized, 10 had half maximal effective concentration (EC) values between 0.
View Article and Find Full Text PDFHuman cell surface-AAV interactomes identify LRP6 as blood-brain barrier transcytosis receptor and immune cytokine IL3 as AAV9 binder.
Nat Commun
September 2024
Division of Biology & Biological Engineering, California Institute of Technology, Pasadena, CA, 91125, USA.
Article Synopsis
- Adeno-associated viruses (AAVs) are important tools used for delivering genes in research and clinical settings, but understanding how these viruses interact with cells can be challenging, especially for those that have been modified through directed evolution.
- This study uses a human cell microarray platform to uncover how both natural and engineered AAVs connect with human cell receptors, discovering that AAV9 specifically interacts with interleukin 3 (IL3) and that engineered AAVs can interact with the low-density lipoprotein receptor-related protein 6 (LRP6), which might enhance their ability to cross the blood-brain barrier.
- The findings also highlight potential side effects from engineered AAVs due to off-target tissue binding, paving the
Dynamic features of virus protein 1 and substitutions in the 3-phenyl ring determine the potency and broad-spectrum activity of capsid-binding pyrazolo[3,4-d]pyrimidines against rhinoviruses.
Antiviral Res
November 2024
Jena University Hospital, Institute of Medical Microbiology, Section Experimental Virology, Hans-Knoell-Str. 2, 07743, Jena, Germany. Electronic address:
Pyrazolo[3,4-d]pyrimidines represent one potent class of well tolerated and highly active rhinovirus (RV) inhibitors that act as capsid binders. The lead compound OBR-5-340 inhibits a broad-spectrum of RVs. Aiming to improve lead activity, we evaluated the impact of structural modifications in the 3-phenyl ring of OBR-5-340 on its potency and spectrum of anti-RV activity vitro.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!